Establishment of the optimal administration method for anticancer agents by proteomics and metabolomics
Project/Area Number |
23590640
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Applied pharmacology
|
Research Institution | Kobe University |
Principal Investigator |
MINAMI Hironobu 神戸大学, 医学(系)研究科(研究院), 教授 (60450574)
|
Co-Investigator(Kenkyū-buntansha) |
MUKOUHARA Toru 神戸大学, 医学部附属病院, 特命准教授 (80435718)
YOSHIDA Masaru 神戸大学, 大学院医学研究科, 准教授 (00419475)
|
Project Period (FY) |
2011 – 2013
|
Project Status |
Completed (Fiscal Year 2013)
|
Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2012: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2011: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
Keywords | 乳がん / 化学療法 / 末梢神経毒性 / 抗腫瘍効果 / プロテオーム解析 / パクリタキセル / 乳癌 / プロテオーム / 臨床薬理学 |
Research Abstract |
Proteomics was investigated to identify proteins which were associated with efficacy and toxicities of the primary systemic chemotherapy with weekly paclitaxel in patients with early breast cancer. Paclitaxel was given at 80 mg/m2, and plasma was obtained before the treatment and 6-8 days after the first administration of paclitaxel. Toxicities were monitored weekly. Among 20 patients, good PR was achieved in 4 and grade 2 or greater peripheral neuropathy was observed in 9. The greatest difference between responders and non-responders was observed in concentrations of Fibulin-1, and Dynein heavy chain 7 showed the greatest correlation to peripheral neuropathy. Patients with a lower concentration of Dynein heavy chain 7 was associated with a higher risk of peripheral neuropathy, and its concentration was increased after the start of the treatment in 5 of 7 patients who experienced neuropathy. Fibulin-1 was also significantly associated with peripheral neuropathy.
|
Report
(4 results)
Research Products
(16 results)
-
[Journal Article] Pathologic complete response after neoadjuvant chemotherapy in HER2-overexperssing breast cancer according to hormonal receptor status2014
Author(s)
Tanioka M, Sasaki M, Shimomura A, Fujishima M, Doi M, Matsuura K, Sakuma T, Yoshimura K, Saeki T, Ohara M, Tsurutani J, Watatani M, Takano T, Kawabata H, Mukai H, Naito Y, Hirokaga K, Takao S, Minami H
-
Journal Title
Breast(Epub)
Volume: 23
Issue: 4
Pages: 466-472
DOI
Related Report
Peer Reviewed
-
[Journal Article] Barriers and challenges to global clinical cancer research2014
Author(s)
Seruga B, Sadikov A, Cazap EL, Delgado LB, Digumarti R, Leighl NB, Meshref MM, Minami H, Robinson E, Yamaguchi NH, Pyle D, Cufer T
-
Journal Title
Oncologist
Volume: 19(1)
Pages: 61-7
Related Report
Peer Reviewed
-
[Journal Article] Excessive MET signaling causes acquired resistance and addiction to MET inhibitors in the MKN45 gastric cancer cell line2013
Author(s)
Funakoshi Y, Mukohara T, Tomioka H, Ekyalongo RC, Kataoka Y, Inui Y, Kawamori Y, Toyoda M, Kiyota N, Fujiwara Y, Minami H
-
Journal Title
Invest New Drugs
Volume: 31 (5)
Pages: 1158-68
Related Report
Peer Reviewed
-
[Journal Article] A novel serum metabolomics-based diagnostic approach to pancreatic cancer2013
Author(s)
Kobayashi T, Nishiumi S, Ikeda A, Yoshie T, Sakai A, Matsubara A, Izumi Y, Tsumura H, Tsuda M, Nishisaki H, Hayashi N, Kawano S, Fujiwara Y, Minami H, Takenawa T, Azuma T, Yoshida M
-
Journal Title
Cancer Epidemiology Biomarkers & Prevention
Volume: 22
Pages: 571-579
Related Report
Peer Reviewed
-
-
-
[Journal Article] A novel serum metabolomics-based diagnostic approach to pancreatic cancer.2013
Author(s)
Kobayashi T, Nishiumi S, Ikeda A, Yoshie T, Sakai A, Matsubara A, Izumi Y, Tsumura H, Tsuda M, Nishisaki H, Hayashi N, Kawano S, Fujiwara Y, Minami H, Takenawa T, Azuma T, Yoshida M.
-
Journal Title
Cancer Epidemiology Biomarkers & Prevention
Volume: 22
Pages: 571-579
Related Report
-
-
-
[Journal Article] Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks2012
Author(s)
Kataoka Y, Mukohara T, Tomioka H, Funakoshi Y, Kiyota N, Fujiwara Y, Yashiro M, Hirakawa K, Hirai M, Minami H
-
Journal Title
Invest New Drugs
Volume: 30 (4)
Pages: 1352-1360
Related Report
Peer Reviewed
-
-
-
-
[Presentation] Pathologic complete response to cisplatin with dose-dense paclitaxel as neoadjuvant chemotherapy for locally advanced cervical cancer: Preliminary results of a multicenter phase II study with additional mutation analysis of adeno/adenosquamous carcinoma.2013
Author(s)
Tanioka M, Yamaguchi S, Sato S, Nagao S, Takehara K, Nishimura M, Sudo T, Morita S, Minami H, Negoro S, Shimada M, Kigawa J, Fujiwara K.
Organizer
Am Soc Clin Oncol
Place of Presentation
Chicago
Related Report
-
[Presentation] Excessive MET signaling causes acquired resistance to and addiction to MET inhibitors in MKN45 gastric cancer cell line2012
Author(s)
Funakoshi Y, Mukohara T, Tomioka H, Ekyalonog RC, Kataoka Y, Inui Y, Kawamori Y, Kiyota N, Fujiwara Y, Minami H
Organizer
24rh EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Place of Presentation
Dublin, Ireland
Related Report
-